Executive Profile*

Cindy Jacobs Ph.D., M.D.

This person is connected to 0 board members in 0 different organizations across 1 different industries.

56

$1,035,702As of Fiscal Year 2013

Background*

Dr. Cindy Jacobs, Ph.D., M.D., has been Executive Vice President and Chief Medical Officer of OncoGenex Pharmaceuticals, Inc. (also known as Oncogenex Technologies Inc.) since August 2008. Dr. Jacobs has more than 20 years of biotechnology industry experience. Dr. Jacobs served as Senior Vice President of Clinical Development and Chief Medical Officer at GSK Biologicals Seattle (formerly Corixa Corp.) now a subsidiary of GlaxoSmithKline, since January 2005, where she ... oversaw a team that obtained Canadian approval for Melacine, a cancer vaccine for melanoma, and two U.S. approvals for BEXXAR, a treatment for patients with refractory and relapsed non-Hodgkin's lymphoma. Dr. Jacobs served as a Senior Vice President of Clinical Research of Corixa Corp. from January 2001 to December 2004. From April 1999 to December 2000, Dr. Jacobs served as the Vice President and Director of Clinical Research at Corixa Corp. Dr. Jacobs served as a Vice President of Clinical Research of Cytran Inc. From 1993 to 1998, she directed clinical research at CellPro, Inc. Dr. Jacobs served as the Vice President of Clinical Research of CellPro, Inc. where she coordinated an international team that achieved both European and U.S. approvals of the CEPRATE SC Stem Cell System for use in bone marrow and peripheral blood transplantation. She also held a number of management positions at Immunex, (now known as Amgen), where she was responsible for preclinical development of the rheumatoid arthritis drug today marketed as Enbrel. Dr. Jacobs graduated from Montana State University, M.S. from Washington State University, Ph.D. in Veterinary Pathology and Microbiology from Washington State University and an M.D. from the University of Washington Medical School.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.